Developing an effective breast cancer vaccine: Challenges to achieving sterile immunity versus resetting equilibrium

Breast

Volumn 22, Issue S2, 2013, Pages

  Curigliano, Giuseppe ^a   Criscitiello, Carmen ^a   Esposito, Angela ^a   Fumagalli, Luca ^a   Gelao, Lucia ^a   Locatelli, Marzia ^a   Minchella, Ida ^a   Goldhirsch, Aron ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Breast cancer; Immune modulation; Therapeutic vaccination

Indexed keywords

CANCER VACCINE; CD4 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; INTERLEUKIN 2 RECEPTOR ALPHA; IPILIMUMAB; SIPULEUCEL T; TRANSCRIPTION FACTOR FOXP3; TUMOR ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER IMMUNIZATION; CANCER IMMUNOEDITING; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; DISEASE ASSOCIATION; DRUG APPROVAL; DRUG TARGETING; EFFECTOR CELL; HUMAN; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOPATHOLOGY; IMMUNOPHENOTYPING; IMMUNOSURVEILLANCE; LYMPHOCYTE FUNCTION; MELANOMA; MOLECULAR INTERACTION; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; RESETTING EQUILIBRIUM; TUMOR ELIMINATION; TUMOR ESCAPE; TUMOR IMMUNITY;

BREAST CANCER; IMMUNE MODULATION; THERAPEUTIC VACCINATION;

BREAST NEOPLASMS; CANCER VACCINES; FEMALE; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNOMODULATION; IMMUNOTHERAPY, ACTIVE; MALE; MELANOMA; NEEDS ASSESSMENT; PROGNOSIS; PROSTATIC NEOPLASMS; SKIN NEOPLASMS; TUMOR MICROENVIRONMENT; VACCINATION;

EID: 84884710173     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2013.07.018     Document Type: Article

References (18)

1. Mellman I., Coukos G., Dranoff G. Cancer immunotherapy comes of age. Nature 2011, 480:480-489.
2. Yang L., Pang Y., Moses H.L. TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol 2010, 31:220-227.
3. Shields J.D., Kourtis I.C., Tomei A.A., Roberts J.M., Swartz M.A. Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21. Science 2010, 328:749-752.
4. Mougiakakos D., Choudhury A., Lladser A., Kiessling R., Johansson C.C. Regulatory T cells in cancer. Adv Cancer Res 2010, 107:57-117.
5. Ostrand-Rosenberg S., Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. JImmunol 2009, 182:4499-4506.
6. DeNardo D.G., Coussens L.M. Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res 2007, 9:212.
7. Sakaguchi S., Yamaguchi T., Nomura T., Ono M. Regulatory T cells and immune tolerance. Cell 2008, 133:775-787.
8. Horwitz D.A. Regulatory T cells in systemic lupus erythematosus: past, present and future. Arthritis Res Ther 2008, 10:227.
9. Campbell Daniel J., Koch Meghan A. Phenotypical and functional specialization of FOXP3+ regulatory T cells. Nat Rev Immunol 2011, 11:119-130.
10. Viglietta V., Baecher-Allan C., Weiner H.L., Hafler D.A. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. JExp Med 2004, 199:971-979.
11. Ehrenstein M.R., Evans J.G., Singh A., Moore S., Warnes G., Isenberg D.A., et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFα therapy. J. Exp. Med 2004, 200:277-285.
12. Lindley S., et al. Defective suppressor function in CD4+CD25+ T-cells from patients with type 1 diabetes. Diabetes 2005, 54:92-99.
13. Merlo A., Casalini P., Carcangiu M.L., Malventano C., Triulzi T., Mènard S., et al. FOXP3 Expression and Overall Survival in Breast Cancer. J Clin Oncol 2009, 29:1746-1752.
14. Acres B., Limacher J.M., Bonnefoy J. Discovery and development of therapeutic cancer vaccines. Curr Opin Drug Discov Devel 2007, 10(2):185-192.
15. Curigliano G., Spitaleri G., Pietri E., Rescigno M., de Braud F., Cardillo A., et al. Breast cancer vaccines: a clinical reality or fairy tale?. Ann. Oncol 2006, 17(5):750-762.
16. Lyerly H.K. Quantitating cellular immune response to cancer vaccines. Sem Oncol 2003, 30(3 suppl 8):9-16.
17. Emens L.A., Reilly R.T., Jaffee E.M. Augmenting the potency of breast cancer vaccines: combined modality immunotherapy. Breast Dis 2004, 20:13-24.
18. Jaini Ritika, Kesaraju Pavani, Johnson Justin M., Altuntas Cengiz Z., Jane-wit Daniel, Tuohy Vincent K. An autoimmune-mediated strategy for prophylactic breast cancer vaccination. Nat Med 2010, 16:799-804.